pyrazines has been researched along with Neurodegenerative Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Campanella, M; Faccenda, D; Singh, A | 1 |
| Chen, H; Meng, S; Meng, Z | 1 |
| Aizawa, H; Ito, Y; Mitani, A; Shimizu, T; Soma, M; Sugimoto, J; Sugiyama, K; Tanaka, K; Tanaka, M | 1 |
| Berciano, MT; Casafont, I; Lafarga, M; Palanca, A | 1 |
| Hoseki, J; Maharjan, S; Oku, M; Sakai, Y; Tsuda, M | 1 |
| Barbera, S; Bigini, P; De Paola, M; Fumagalli, E; Mennini, T | 1 |
| Gharibzadeh, S; Hoseini, SS; Mahdavi, S | 1 |
2 review(s) available for pyrazines and Neurodegenerative Diseases
| Article | Year |
|---|---|
Pharmacological advances in mitochondrial therapy.
Topics: Antioxidants; Humans; Mitochondria; Mitochondrial Diseases; Mitochondrial Dynamics; Neurodegenerative Diseases; Oxidative Phosphorylation; Pyrazines; Ubiquinone | 2021 |
The Roles of Tetramethylpyrazine During Neurodegenerative Disease.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Humans; Neurodegenerative Diseases; Pyrazines; Vasodilator Agents | 2021 |
5 other study(ies) available for pyrazines and Neurodegenerative Diseases
| Article | Year |
|---|---|
Region-specific deletions of the glutamate transporter GLT1 differentially affect seizure activity and neurodegeneration in mice.
Topics: Animals; Anticonvulsants; Brain; Cell Death; Disease Models, Animal; DNA-Binding Proteins; Excitatory Amino Acid Transporter 2; Forkhead Transcription Factors; Homeodomain Proteins; Male; Mice, Inbred C57BL; Mice, Knockout; Nerve Tissue Proteins; Neurodegenerative Diseases; Neurons; Nuclear Proteins; Pentylenetetrazole; Pyrazines; Receptors, N-Methyl-D-Aspartate; Seizures; Transcription Factors | 2018 |
Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons.
Topics: Animals; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Nucleolus; Cell Nucleus; Coiled Bodies; Cytoplasm; Ganglia, Sensory; Humans; Neurodegenerative Diseases; Proteasome Endopeptidase Complex; Pyrazines; Rats; Sensory Receptor Cells; Signal Transduction | 2014 |
Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition.
Topics: Animals; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; CHO Cells; Cricetinae; Cricetulus; Membrane Potential, Mitochondrial; Mitochondria; Neurodegenerative Diseases; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Reactive Oxygen Species; Resveratrol; Stilbenes; Ubiquitination | 2014 |
Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease.
Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; CD11b Antigen; Cell Death; Choline O-Acetyltransferase; Disease Models, Animal; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Imidazoles; Immunohistochemistry; Mice; Mice, Neurologic Mutants; Motor Activity; Motor Neurons; Neurodegenerative Diseases; Psychomotor Performance; Pyrazines; Radioimmunoassay; Riluzole | 2006 |
Oltipraz may be useful in the prevention or treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Humans; Mice; Neurodegenerative Diseases; Oxidative Stress; Pyrazines; Schistosomicides; Thiones; Thiophenes | 2007 |